Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma

Invest New Drugs. 1991 Feb;9(1):69-72. doi: 10.1007/BF00194548.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / adverse effects
  • Azacitidine / analogs & derivatives*
  • Azacitidine / therapeutic use
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Mesothelioma / drug therapy*
  • Middle Aged
  • Pleural Neoplasms / drug therapy*

Substances

  • Antimetabolites, Antineoplastic
  • 5,6-dihydro-5-azacytidine
  • Azacitidine